Cigna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied due to quantity / dose limits by Cigna?

Q: How long do I have to appeal a Cigna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

T2DM diagnosis required (CNF-749); HbA1c ≥6.5% consistent with ADA.

Source policy: Cigna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Cigna angle on Tirzepatide

## Cigna Quantity Limit Denials on Tirzepatide: The Express Scripts/Accredo Edit Layer

Quantity-limit denials on tirzepatide under Cigna are almost never adjudicated by Cigna Healthcare's medical division — they are PBM-side edits administered by Express Scripts with specialty fulfillment routed through Accredo. The relevant document is Cigna Coverage Policy IP0554 (Tirzepatide — Mounjaro) and Coverage Position 2031 (Glucagon-Like Peptide-1 Agonists), both of which cap dispensing at one carton (four pens) per 28 days consistent with the FDA-approved titration schedule (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, escalated no more frequently than every four weeks). If your pharmacy submits a 30-day or 90-day fill that exceeds this ratio — or attempts a same-dose refill before the 23rd day of supply — the Express Scripts adjudication engine returns reject code 76 (Plan Limitations Exceeded) or NCPDP 79 (Refill Too Soon).

The denial mechanic matters because the appeal path is dose-step specific. If the prescriber wrote a dose escalation that bypasses an intermediate titration step (e.g., 5 mg → 10 mg skipping 7.5 mg), the QL edit will fire even though Cigna's CNF-749 prior authorization for T2DM (HbA1c ≥ 6.5% per ADA Standards of Care §2) is fully satisfied. The override is not a clinical appeal — it is a quantity-limit exception filed through Express Scripts' PA portal (CoverMyMeds or ESI's PromptPA), citing the FDA label Section 2.2 dosing schedule and prescriber documentation that the patient tolerated the prior dose for ≥4 weeks.

For commercial ERISA plans, the procedural rails are 29 CFR §2560.503-1 — Cigna/Express Scripts owes a written denial within 15 days (pre-service) and must disclose the specific QL ratio relied upon. Demand the clinical review criteria document in writing; ESI routinely cites "plan limits" without producing the underlying days-supply algorithm, which is a §2560.503-1(g)(1)(v)(B) violation. For Cigna Medicare Advantage / Part D plans, the override request is governed by 42 CFR §423.578(b) (tiering/QL exceptions) with a 72-hour standard / 24-hour expedited turnaround.

If the denial persists after the QL exception, escalate to Cigna Healthcare Appeals (not ESI) on a parity theory: tirzepatide for T2DM is a medical-surgical benefit, and arbitrary refill-too-soon edits that exceed FDA labeling can constitute an NQTL violation under 29 CFR §2590.712. Pinto v. Aetna logic also applies — the plan bears the burden to justify the quantitative restriction with evidence.

Tactical tip: Pull the Accredo dispense history before appealing and calculate the actual days-supply consumed. ESI's edit is often triggered by a pharmacy-side billing error (4 pens billed as 28-day supply when patient is on weekly dosing = correct; billed as 7-day supply = QL fires immediately). Fix the days-supply field at the pharmacy counter before escalating clinically.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other insurers on Tirzepatide

Other denial reasons for Cigna Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.